GlassScriptPhysician profile
Emily Carter
NPI 1033991229
$5,025.10
in general payments reported to CMS, 2019-2025
43 companies · $2,805 in 2025
The $2,805 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $50.39 · 2024: $2,169 · 2025: $2,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,255 · Education: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.25 |
| Education | $769.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.95 | 2024-2025 | Enhertu, Tagrisso, Calquence |
| Incyte Corporation | $635.07 | 2024-2025 | Monjuvi, Jakafi, Jakafi |
| Abbvie INC. | $318.83 | 2024-2025 | |
| Janssen Biotech, INC. | $283.12 | 2024-2025 | Imbruvica, Erleada, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $255.25 | 2024 | |
| Servier Pharmaceuticals LLC | $214.88 | 2025 | |
| Pharmacosmos Therapeutics INC. | $199.58 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $193.24 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Seagen INC. | $187.98 | 2024 | |
| Genzyme Corporation | $180.14 | 2024-2025 | |
| Geron Corporation | $156.94 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $145.87 | 2025 | Brukinsa |
| Novocure INC. | $144.30 | 2025 | Optune Gio |
| Dendreon Pharmaceuticals LLC | $143.77 | 2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $123.74 | 2024 | Libtayo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $122.90 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $104.74 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Aveo Pharmaceuticals, INC. | $102.38 | 2025 | |
| Stemline Therapeutics INC. | $91.43 | 2024 | Orserdu |
| Novartis Pharmaceuticals Corporation | $81.58 | 2025 | |
| Daiichi Sankyo INC. | $76.36 | 2025 | Enhertu, Datroway |
| Axonics, INC. | $50.39 | 2023 | Axonics |
| Agios Pharmaceuticals, INC. | $47.02 | 2025 | Pyrukynd |
| Genentech USA, INC. | $43.77 | 2025 | Phesgo, Venclexta |
| Lilly USA, LLC | $36.36 | 2025 | Verzenio, Jaypirca |
| Boston Scientific Corporation | $36.12 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Sobi, INC | $34.17 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.86 | 2025 | |
| Emd Serono, INC. | $27.83 | 2025 | |
| Tersera Therapeutics LLC | $27.75 | 2024 | Zoladex |
| Immunocore Limited | $25.88 | 2025 | Kimmtrak |
| Genmab U.S., INC. | $23.20 | 2024 | Epkinly |
| Gilead Sciences, INC. | $23.18 | 2024 | |
| Taiho Oncology, INC. | $22.80 | 2025 | |
| Adc Therapeutics America, INC. | $20.49 | 2025 | |
| Puma Biotechnology, INC. | $19.01 | 2025 | |
| Exelixis INC. | $19.00 | 2024 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $18.73 | 2025 | Ultomiris |
| Pharmaessentia USA Corporation | $18.07 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $16.62 | 2025 | Xpovio |
| Tempus Ai, INC | $16.44 | 2025 | Xt Cdx |
| Legend Biotech USA INC. | $14.36 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $14.00 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.